12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersTevogen Bio Holdings (NASDAQ:TVGN) shares rose 75.3% to $1.49 during Friday's pre-market session. The company's market cap stands at $245.2 million. Cryo-Cell International (AMEX:CCEL) shares i
Analysts Offer Insights on Healthcare Companies: Genprex (GNPX) and SurModics (SRDX)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Evaxion Biotech (EVAX), 60 Degrees Pharmaceuticals, Inc. (SXTP) and Genprex (GNPX)
HC Wainwright & Co. Reiterates Buy on Genprex, Maintains $10 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Genprex (NASDAQ:GNPX) with a Buy and maintains $10 price target.
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination With Tecentriq to Treat Small Cell Lung Cancer
Multiple clinical trial sites to be opened under collaboration with large network of community-based oncology practices Acclaim-3 Study Supported by FDA Orphan Drug a
Genprex Collaborators Publish Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Oncoprex Delivery System
NPRL2 Gene Therapy Induces Anti-Tumor Activity in Anti-PD1 Resistant KRAS/STK11 Mutant Non-Small Cell Lung Cancer in a Humanized Mouse Model Provides Additional Preclinical Validati
Genprex Initiated at Buy by HC Wainwright & Co.
Genprex Initiated at Buy by HC Wainwright & Co.
HC Wainwright & Co. Initiates Coverage On Genprex With Buy Rating, Announces Price Target of $10
HC Wainwright & Co. analyst Yi Chen initiates coverage on Genprex with a Buy rating and announces Price Target of $10.
Genprex Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/25/2024 216.46% HC Wainwright & Co. → $10 Initiates Coverage On → Buy 01/30/2023 -5.06% Dawson James →
Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
AUSTIN, Texas — (March 22, 2024) — Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients wi
Genprex Shares Drop 12% on Latest Stock Offering to Get Proceeds of $5.8M
By Sabela Ojea Shares of Genprex on Wednesday dropped after the company agreed to sell common shares and warrants to purchase shares to raise net proceeds of about $5.8 million. In recent trading, s
JAGX and GNPX Among Health Care Movers
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersOntrak (NASDAQ:OTRK) shares increased by 97.6% to $0.38 during Tuesday's regular session. The market value of their outstanding shares is at $10.3 million. Fusion Pharmaceuticals (NASDAQ:FUSN)
Genprex Shares Hit 52-Week Low After Direct Offering Prices
By Chris Wack Genprex shares were down 17% at $3.41, a 52-week low, after the company priced a registered direct offering expected to generate proceeds of $6.5 million. The stock is down 89% in the
Genprex Launches $6.5 Million Securities Offering; Shares Fall
Genprex (GNPX) said Tuesday it launched a stock offering to raise $6.5 million. The offering of 1.54 million common shares and accompanying warrants was priced at $4.215 a share, the company said. The
Genprex Falls 10% After Pricing Its Offering to Raise $6.5M
Genprex Announces $6.5M Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Genprex Announces $6.5M Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
AUSTIN, Texas — (March 19, 2024) — Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients wi
Genprex Receives Notice Of Patent Grant For Korean Patent Claiming Reqorsa Immunogene Therapy With PD-1 And PD-L1 Antibodies To Treat Cancers
Genprex Receives Notice Of Patent Grant For Korean Patent Claiming Reqorsa Immunogene Therapy With PD-1 And PD-L1 Antibodies To Treat Cancers
Genprex Collaborators To Present Preclinical Data On Use Of Reqorsa And On NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System For Lung Cancers At 2024 AACR Annual Meeting
Reqorsa Immunogene Therapy May be a Potential Therapy for ALK-Positive Lung CancerREQORSA has Anti-Tumor Mechanisms that Target and Disrupt the Metabolism of Cancer CellsNPRL2 Gene Therapy Induces Eff
No Data